Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Laura Bao Pérez"'
Autor:
Adrián Mosquera Orgueira, Jose Ángel Díaz Arías, Rocio Serrano Martín, Victor Portela Piñeiro, Miguel Cid López, Andrés Peleteiro Raíndo, Laura Bao Pérez, Marta Sonia González Pérez, Manuel Mateo Pérez Encinas, Máximo Francisco Fraga Rodríguez, Juan Carlos Vallejo Llamas, José Luis Bello López
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
Diffuse Large B-cell Lymphoma (DLBCL) is the most common type of aggressive lymphoma. Approximately 60% of fit patients achieve curation with immunochemotherapy, but the remaining patients relapse or have refractory disease, which predicts a short su
Externí odkaz:
https://doaj.org/article/617f5691a8e74047b11c6b9eeaa33179
Autor:
Adrián Mosquera Orgueira, José Ángel Díaz Arias, Miguel Cid López, Andrés Peleteiro Raíndo, Beatriz Antelo Rodríguez, Carlos Aliste Santos, Natalia Alonso Vence, Ángeles Bendaña López, Aitor Abuín Blanco, Laura Bao Pérez, Marta Sonia González Pérez, Manuel Mateo Pérez Encinas, Máximo Francisco Fraga Rodríguez, José Luis Bello López
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-9 (2020)
Abstract Background Thirty to forty percent of patients with Diffuse Large B-cell Lymphoma (DLBCL) have an adverse clinical evolution. The increased understanding of DLBCL biology has shed light on the clinical evolution of this pathology, leading to
Externí odkaz:
https://doaj.org/article/47def9812b5e4561b9a2ffba19e04710
Autor:
Adrián Mosquera Orgueira, Andrés Peleteiro Raíndo, Miguel Cid López, Beatriz Antelo Rodríguez, José Ángel Díaz Arias, Roi Ferreiro Ferro, Natalia Alonso Vence, Ángeles Bendaña López, Aitor Abuín Blanco, Laura Bao Pérez, Paula Melero Valentín, Marta Sonia González Pérez, Claudio Cerchione, Giovanni Martinelli, Pau Montesinos Fernández, Manuel Mateo Pérez Encinas, José Luis Bello López
Publikováno v:
PLoS ONE, Vol 17, Iss 9 (2022)
Externí odkaz:
https://doaj.org/article/7621093bf9e0435ab51db257b2df8022
Autor:
Adrián Mosquera Orgueira, Miguel Cid López, Andrés Peleteiro Raíndo, Aitor Abuín Blanco, Jose Ángel Díaz Arias, Marta Sonia González Pérez, Beatriz Antelo Rodríguez, Laura Bao Pérez, Roi Ferreiro Ferro, Carlos Aliste Santos, Manuel Mateo Pérez Encinas, Máximo Francisco Fraga Rodríguez, Claudio Cerchione, Pablo Mozas, José Luis Bello López
Publikováno v:
Frontiers in Oncology, Vol 11 (2022)
Follicular Lymphoma (FL) has a 10-year mortality rate of 20%, and this is mostly related to lymphoma progression and transformation to higher grades. In the era of personalized medicine it has become increasingly important to provide patients with an
Externí odkaz:
https://doaj.org/article/946e64e6f3364a31836120ae590b10a7
Autor:
Adrián Mosquera Orgueira, Andrés Peleteiro Raíndo, Miguel Cid López, José Ángel Díaz Arias, Marta Sonia González Pérez, Beatriz Antelo Rodríguez, Natalia Alonso Vence, Laura Bao Pérez, Roi Ferreiro Ferro, Manuel Albors Ferreiro, Aitor Abuín Blanco, Emilia Fontanes Trabazo, Claudio Cerchione, Giovanni Martinnelli, Pau Montesinos Fernández, Manuel Mateo Pérez Encinas, José Luis Bello López
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Acute Myeloid Leukemia (AML) is a heterogeneous neoplasm characterized by cytogenetic and molecular alterations that drive patient prognosis. Currently established risk stratification guidelines show a moderate predictive accuracy, and newer tools th
Externí odkaz:
https://doaj.org/article/0c2126a43e2b4b08bd36aea5a3a142eb
Autor:
Adrián Mosquera Orgueira, Roi Ferreiro Ferro, José Ángel Díaz Arias, Carlos Aliste Santos, Beatriz Antelo Rodríguez, Laura Bao Pérez, Natalia Alonso Vence, Ággeles Bendaña López, Aitor Abuin Blanco, Paula Melero Valentín, And Res Peleteiro Raindo, Miguel Cid López, Manuel Mateo Pérez Encinas, Marta Sonia González Pérez, Máximo Francisco Fraga Rodríguez, José Luis Bello López
Publikováno v:
PLoS ONE, Vol 16, Iss 5, p e0248886 (2021)
B-cell lymphoproliferative disorders exhibit a diverse spectrum of diagnostic entities with heterogeneous behaviour. Multiple efforts have focused on the determination of the genomic drivers of B-cell lymphoma subtypes. In the meantime, the aggregati
Externí odkaz:
https://doaj.org/article/754ac779e90d4b05b34d220930ad3e5d
Autor:
Adrián Mosquera Orgueira, Andrés Peleteiro Raíndo, Miguel Cid López, Beatriz Antelo Rodríguez, José Ángel Díaz Arias, Roi Ferreiro Ferro, Natalia Alonso Vence, Ángeles Bendaña López, Aitor Abuín Blanco, Laura Bao Pérez, Paula Melero Valentín, Marta Sonia González Pérez, Claudio Cerchione, Giovanni Martinelli, Pau Montesinos Fernández, Manuel Mateo Pérez Encinas, José Luis Bello López
Publikováno v:
PLoS ONE, Vol 16, Iss 2, p e0247093 (2021)
BackgroundFLT3 mutation is present in 25-30% of all acute myeloid leukemias (AML), and it is associated with adverse outcome. FLT3 inhibitors have shown improved survival results in AML both as upfront treatment and in relapsed/refractory disease. Cu
Externí odkaz:
https://doaj.org/article/cbe01aa7d0234032abc58f5a46490841
Autor:
Jose Luis Bello Lopez, Adrian Mosquera Orgueira, Roi Ferreiro Ferro, Miguel Cid López, José Ángel Díaz Arias, Beatriz Antelo Rodríguez, Laura Bao Pérez, Carlos Aliste Santos, Manuel Mateo Pérez Encinas, Natalia Alonso Vence, Ángeles Bendaña López, Maximo Francisco Fraga Martinez, Aitor Abuin Blanco, Paula Melero Valentín, Andrés Peleteiro Raíndo, Marta Sonia González Pérez
Growing evidence has revealed the implication of germline variation in cancer predisposition and prognostication. Here, we describe an analysis of putatively disruptive rare variants across the genomes of 726 patients with B-cell lymphoid neoplasms.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::adac61c885a683d4b706fbfc63db51c9
Autor:
Aitor Abuin Blanco, Ángeles Bendaña López, Adrián Mosquera Orgueira, Giovanni Martinelli, Andrés Peleteiro Raíndo, Laura Bao Pérez, Natalia Alonso Vence, José Luis Bello López, Marta Sonia González Pérez, Roi Ferreiro Ferro, Miguel Cid López, José Ángel Díaz Arias, Pau Montesinos Fernández, Claudio Cerchione, Paula Melero Valentín, Beatriz Antelo Rodríguez, Manuel Mateo Pérez Encinas
Publikováno v:
PLoS ONE, Vol 16, Iss 2, p e0247093 (2021)
PLoS ONE
PLoS ONE
Background FLT3 mutation is present in 25–30% of all acute myeloid leukemias (AML), and it is associated with adverse outcome. FLT3 inhibitors have shown improved survival results in AML both as upfront treatment and in relapsed/refractory disease.
Autor:
Maria Victoria Mateos Manteca, Ángeles Bendaña López, Beatriz Antelo Rodríguez, José Ángel Díaz Arias, Laura Bao Pérez, Adrián Mosquera Orgueira, Marta Sonia González Pérez, Andrés Peleteiro Raíndo, Miguel Cid López, Aitor Abuin Blanco, José Luis Bello López, Natalia Alonso Vence, Manuel Mateo Pérez Encinas
Publikováno v:
Digital.CSIC. Repositorio Institucional del CSIC
instname
instname
Multiple myeloma (MM) remains mostly an incurable disease with a heterogeneous clinical evolution. Despite the availability of several prognostic scores, substantial room for improvement still exists. Promising results have been obtained by integrati